| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10219324 | The Journal of Urology | 2018 | 7 Pages |
Abstract
Patients who receive 5α-reductase inhibitors have improved disease specific survival after bladder cancer diagnosis compared to those who do not receive them while α-blockers were not associated with survival. This supports the benefits of 5α-reductase inhibitors in bladder cancer.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Ville J. Mäkelä, Andres Kotsar, Teuvo L.J. Tammela, Teemu J. Murtola,